The inhibition, which shows dose dependency, is exerted via interactions with receptors in the brain that are accessible via leaks in the blood-brain barrier of the circumventricular organs, mainly the postrema area, the subfornical organ and the median eminence [10, 11]
O'Neil, P.M
doi:10.1111/j.1467-789X.2007.00413.x Smith, R
Goldenberg RM, Ahooja V, Clemens KK, Gilbert JD, Poddar M, Verma S
no melanoma events in over 1,000 treated patients across surveillance periods No serious drug-related events : No consistent serious adverse events attributed to afamelanotide in pivotal trials Melanotan-2 Safety Profile# Melanotan-2 carries substantially more safety concerns: Common effects : Nausea in approximately 38% of injections (severe in approximately 15%)